Compare TENX & RSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TENX | RSSS |
|---|---|---|
| Founded | 1967 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.8M | 71.2M |
| IPO Year | 2001 | 2008 |
| Metric | TENX | RSSS |
|---|---|---|
| Price | $1.48 | $1.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | ★ $10.29 | $3.83 |
| AVG Volume (30 Days) | ★ 1.4M | 35.6K |
| Earning Date | 11-05-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 125.00 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $28,793,922.00 |
| Revenue This Year | N/A | $1.40 |
| Revenue Next Year | N/A | $5.18 |
| P/E Ratio | ★ N/A | $21.00 |
| Revenue Growth | N/A | ★ 2.77 |
| 52 Week Low | $1.31 | $1.77 |
| 52 Week High | $19.40 | $3.38 |
| Indicator | TENX | RSSS |
|---|---|---|
| Relative Strength Index (RSI) | 35.62 | 45.43 |
| Support Level | $1.34 | $1.78 |
| Resistance Level | $2.01 | $2.36 |
| Average True Range (ATR) | 0.12 | 0.09 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 6.25 | 40.00 |
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from the cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.